News
NWPHF
2.100
NaN%
--
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Newron Pharmaceuticals SpA (OtherNWPHF) and Boston Scientific (BSX)
TipRanks · 07/08 10:30
Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide
TipRanks · 07/02 16:03
H.C. Wainwright Sticks to Its Buy Rating for Newron Pharmaceuticals SpA (NWPHF)
TipRanks · 06/25 12:36
Analysts’ Top NA Picks: Newron Pharmaceuticals SpA (NWPHF), Veradermics, Incorporated (MANE)
TipRanks · 06/22 10:44
Newron Pharmaceuticals SpA (NWPHF) Receives a Buy from H.C. Wainwright
TipRanks · 06/22 10:41
Newron Pharmaceuticals SpA (NWPHF) Gets a Buy from H.C. Wainwright
TipRanks · 06/11 13:06
Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright
TipRanks · 05/04 10:16
FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death
TipRanks · 04/29 16:05
Newron Shareholders Back Board Changes at 2026 General Meeting
TipRanks · 04/23 13:35
Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
TipRanks · 03/27 00:18
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
TipRanks · 03/25 10:16
Newron bolsters finances as Evenamide enters pivotal global Phase III
TipRanks · 03/24 06:34
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
TipRanks · 03/24 06:33
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
TipRanks · 03/20 06:33
Newron extends EIB loan maturities to align financing with Evenamide milestones
TipRanks · 03/19 06:35
Newron refreshes board with CNS and capital markets experts ahead of AGM
TipRanks · 03/18 06:34
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
TipRanks · 02/16 17:02
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
TipRanks · 02/16 17:02
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
TipRanks · 02/03 06:33
Analysts Conflicted on These Healthcare Names: Arcturus Therapeutics (ARCT), Newron Pharmaceuticals SpA (OtherNWPHF) and Aldeyra Therapeutics (ALDX)
TipRanks · 01/21 15:20
More
Webull provides a variety of real-time NWPHF stock news. You can receive the latest news about Newron Phar through multiple platforms. This information may help you make smarter investment decisions.
About NWPHF
Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.